Speaker: Eleni Gavriilaki

0:38:32

34yo Woman With B-ALL Who Developed TMA After HSCT and Was Treated With a Complement Inhibitor

0:01:45

ATG versus ATLG as prophylaxis for graft-versus-host disease in alloSCT: a comparative study

0:01:00

The association between hemophilia and fracture risk

0:00:55

Insights into the real-world evidence for C3 inhibition in the treatment of PNH

0:01:53

Real-world analysis of prevalence of fungal infections after cellular therapy

0:00:52

Advances in treatment modalities to reduce the risk of GvHD in allografted patients

0:01:28

Risk factors associated with TA-TMA in patients with GvHD

0:00:58

Agents under investigation for the treatment of TA-TMA

0:01:29

Safety and efficacy of autoSCT in systemic sclerosis

0:01:33

Real-world multicenter study of caplacizumab in patients with acquired TTP

0:01:13

Treosulfan-based conditioning regimens for alloSCT in patients with myeloid malignancies

0:01:19

The potential of caplacizumab in the treatment of aTTP

0:01:22

Updates on the use of narsoplimab in the treatment of TA-TMA

0:00:56

Recent updates on narsoplimab for TA-TMA

0:01:59

Prospective study evaluating complement activation in patients with sickle cell disease

0:01:19

Collaboration between the EBMT Trainee & YoungEHA Committees at the 5th European CAR T-cell Meeting

0:06:11

Diversity, Equity, and Inclusion in Hematology

0:02:00

The future of CAR-T therapy and the role of transplantation within this field

0:01:32

Optimizing transplantation outcomes in patients with AML

0:01:02

The use of CAR-T cell products in a real-world setting

0:01:46

Real-world experiences with toxicity in patients treated with CAR-T cell therapy

0:01:06

Aims of the YoungEHA committee

0:01:19

Narsoplimab increases platelets and decreases LDH in TA-TMA

0:02:03

A look at the ‘Young EBMT and EHA Ambassadors’ Committee